Estudo randomizado | Sugemalimabe melhora a sobrevida livre de progressão vs. placebo em pacientes com câncer metastático de pulmão de não pequenas células.
4 Fev, 2022 | 14:36hSugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial – The Lancet Oncology (link para o resumo – $ para o texto completo)
Estudo relacionado: Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial – The Lancet Oncology (link para o resumo – $ para o texto completo)
Comentários:
Sugemalimab shows promise for locally advanced, metastatic NSCLC – Medicine Matters
Sugemalimab Boosts Outcomes in NSCLC – MedPage Today (necessário cadastro gratuito)
Comentário no Twitter
In the phase III GEMSTONE-302 trial of chemo + sugemalimab or placebo in 479 with untreated advanced-stage NSCLC, mPFS was 9.0 vs 4.9 months (HR 0.48; P<0.0001); OS was 72.4% vs 62.0% at 12 months & 47.1% vs 38.1% at 24 months (HR 0.67, 95% CI 0.50–0.90): https://t.co/z6f00tqy8B
— NatureRevClinOncol (@NatRevClinOncol) January 19, 2022